2-Cyano-3,5-difluoropyridine | CAS:298709-29-2

We serve 2-Cyano-3,5-difluoropyridine CAS:298709-29-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Cyano-3,5-difluoropyridine

Chemical Name:  2-Cyano-3,5-difluoropyridine
CAS.NO: 298709-29-2
Synonyms:3,5-Difluoropyridine-2-carbonitrile;
3,5-difluoro-2-cyano pyridine;
3,5-difluoronicotinonitrile;
3,5-DIFLUORO-2-PYRIDINECARBONITRILE;
3,5-Difluoropicolinitrile;
Molecular Formula:C6H2F2N2
Molecular Weight:140.09000
 
Physical and Chemical Properties:
Density: 1.4±0.1 g/cm3
Melting point:32-34°C
Boiling point: 187.8±35.0 °C at 760 mmHg
Flash point:67.4±25.9 °C
Index of Refraction: 1.483
 
Specification:
Appearance: Powder
Purity:≥98.0%
 
Packing:25 KGS/Drum
Storage:Store in a tightly closed container. Store in a cool, dry.
Application:    used to Pharmaceutical intermediate



Contact us for information like 2-Cyano-3,5-difluoropyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3,5-Difluoropicolinitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3,5-Difluoropyridine-2-carbonitrile Use and application,2-Cyano-3,5-difluoropyridine technical grade,usp/ep/jp grade.


Related News: In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.2,2'-dibromo-9,9'-spirobi[fluorene] manufacturer According to the “2013-2018 New Drug Review Summary” report, from 2013 to 2018, new drug applications have shown a year-on-year growth trend. In 2018, domestically produced Class 1 new drugs have declared 225 varieties, the highest in 10 years.(7-methoxy-4-oxo-1H-quinazolin-6-yl) acetate supplier According to the “2013-2018 New Drug Review Summary” report, from 2013 to 2018, new drug applications have shown a year-on-year growth trend. In 2018, domestically produced Class 1 new drugs have declared 225 varieties, the highest in 10 years.N-((6-Chloropyridin-3-yl)methyl)ethanamine vendor “Traditional medicine is a treasure of Chinese civilization embodying the wisdom of the nation and its people,” Xi said at the meeting in Beijing.The company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments.